Kaiser Permanente Evidence-based Practice Center, Kaiser Permanente Center for Health Research, Portland, Oregon.
Gillings School of Global Public Health, University of North Carolina School of Medicine, Chapel Hill.
JAMA. 2023 Jun 27;329(24):2171-2184. doi: 10.1001/jama.2023.6369.
Anxiety is commonly seen in primary care and associated with substantial burden.
To review the benefits and harms of screening and treatment for anxiety and the accuracy of instruments to detect anxiety among primary care patients.
MEDLINE, PsychINFO, Cochrane library through September 7, 2022; references of existing reviews; ongoing surveillance for relevant literature through November 25, 2022.
English-language original studies and systematic reviews of screening or treatment compared with control conditions and test accuracy studies of a priori-selected screening instruments were included. Two investigators independently reviewed abstracts and full-text articles for inclusion. Two investigators independently rated study quality.
One investigator abstracted data; a second checked accuracy. Meta-analysis results were included from existing systematic reviews where available; meta-analyses were conducted on original research when evidence was sufficient.
Anxiety and depression outcomes; global quality of life and functioning; sensitivity and specificity of screening tools.
Of the 59 publications included, 40 were original studies (N = 275 489) and 19 were systematic reviews (including ≈483 studies [N≈81 507]). Two screening studies found no benefit for screening for anxiety. Among test accuracy studies, only the Generalized Anxiety Disorder (GAD) GAD-2 and GAD-7 screening instruments were evaluated by more than 1 study. Both screening instruments had adequate accuracy for detecting generalized anxiety disorder (eg, across 3 studies the GAD-7 at a cutoff of 10 had a pooled sensitivity of 0.79 [95% CI, 0.69 to 0.94] and specificity of 0.89 [95% CI, 0.83 to 0.94]). Evidence was limited for other instruments and other anxiety disorders. A large body of evidence supported the benefit of treatment for anxiety. For example, psychological interventions were associated with a small pooled standardized mean difference of -0.41 in anxiety symptom severity in primary care patients with anxiety (95% CI, -0.58 to -0.23]; 10 RCTs [n = 2075]; I2 = 40.2%); larger effects were found in general adult populations.
Evidence was insufficient to draw conclusions about the benefits or harms of anxiety screening programs. However, clear evidence exists that treatment for anxiety is beneficial, and more limited evidence indicates that some anxiety screening instruments have acceptable accuracy to detect generalized anxiety disorder.
焦虑在初级保健中很常见,与巨大的负担有关。
综述焦虑的筛查和治疗的益处和危害,以及初级保健患者焦虑检测工具的准确性。
截至 2022 年 9 月 7 日,通过 MEDLINE、PsychINFO 和 Cochrane 图书馆进行检索;现有综述的参考文献;截至 2022 年 11 月 25 日,通过持续监测获取相关文献。
纳入了关于筛查或治疗与对照条件的比较以及预先选择的筛查工具的测试准确性研究的英语原始研究和系统综述。两名调查员独立审查摘要和全文文章以确定是否纳入。两名调查员独立评估研究质量。
一名调查员提取数据,另一名调查员检查准确性。如果有现成的系统综述,结果中包含来自现有系统综述的荟萃分析结果;如果证据充足,则对原始研究进行荟萃分析。
焦虑和抑郁结局;总体生活质量和功能;筛查工具的敏感性和特异性。
在纳入的 59 篇出版物中,40 篇为原始研究(N=275489),19 篇为系统综述(包括约 483 项研究[N=81507])。两项筛查研究发现,焦虑筛查没有益处。在测试准确性研究中,只有一般焦虑障碍(GAD)GAD-2 和 GAD-7 筛查工具被超过 1 项研究评估。这两种筛查工具都具有较高的检测广泛性焦虑障碍的准确性(例如,在 3 项研究中,GAD-7 的截断值为 10 时,灵敏度的汇总值为 0.79(95%CI,0.69 至 0.94),特异性为 0.89(95%CI,0.83 至 0.94))。其他工具和其他焦虑障碍的证据有限。大量证据支持焦虑治疗的益处。例如,在有焦虑症状的初级保健患者中,心理干预与焦虑症状严重程度的标准化均数差的汇总值为-0.41(95%CI,-0.58 至-0.23];10 项 RCT [n=2075];I2=40.2%);在一般成年人群中发现了更大的效果。
关于焦虑筛查项目的益处或危害,尚无足够证据得出结论。然而,明确的证据表明,焦虑治疗是有益的,而更有限的证据表明,一些焦虑筛查工具具有可接受的准确性来检测广泛性焦虑障碍。